SCHEMBL17286144

SCHEMBL17286144

C[C@H]1[C@@H](C)CN(c2ccncc2N)C[C@H]1NC(=O)OC(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 2/20 0.39
MAPT P10636 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GLA P06280 1/20 0.38
GAA P10253 1/20 0.38
EIF2AK4 Q9P2K8 1/20 0.38
PIM2 Q9P1W9 8/20 0.37
PIM1 P11309 7/20 0.37
PIM3 Q86V86 7/20 0.37
KDM1A O60341 1/20 0.35
BRS3 P32247 1/20 0.35
KDM4D Q6B0I6 2/20 0.35
PDE10A Q9Y233 1/20 0.35
CKS1B P61024 1/20 0.34
SKP1 P63208 1/20 0.34
SKP2 Q13309 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16588194 0.92 PIM2 (0.41) MAP4K4MAPTEIF2AK4PIM2PIM1
SCHEMBL16588195 0.89 GPR119 (0.38) MAP4K4EIF2AK4PIM2PIM1PIM3
SCHEMBL15883540 0.89 PIM2 (0.45) MAP4K4MAPTKDM4EALDH1A1GLA
SCHEMBL15588848 0.88 PIM1 (0.40) MAP4K4MAPTEIF2AK4PIM2PIM1
SCHEMBL13456795 0.87 EIF2AK4 (0.40) MAP4K4MAPTKDM4EALDH1A1GLA
SCHEMBL13707585 0.87 EIF2AK4 (0.40) MAP4K4MAPTKDM4EALDH1A1GLA
SCHEMBL19371200 0.86 EIF2AK4 (0.36) MAP4K4MAPTKDM4EALDH1A1GLA
SCHEMBL15818198 0.86 PIM2 (0.36) MAP4K4MAPTKDM4EALDH1A1GLA
SCHEMBL15589027 0.86 PIM2 (0.42) MAP4K4MAPTKDM4EALDH1A1GLA
SCHEMBL18430030 0.86 MAP4K4 (0.35) MAP4K4MAPTKDM4EALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150336960-A1 ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS NOVARTIS AG (CH) 2015-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336960-A1 ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS PIM1, PIM2, PIM3 MAP4K4 13/4885MAPT 82/4885KDM4E 2213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.